GHRP-6vsIpamorelin

GHRP-6 (Growth Hormone Releasing Peptide-6) is one of the earliest synthetic GH secretagogues developed, first characterized in the 1980s. It is a hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that acts as a full agonist at the GHS-R1a receptor, the subsequently identified endogenous receptor for ghrelin. GHRP-6 actually preceded the discovery of ghrelin itself — research on GHRPs led scientists to identify the receptor, which in turn led to the discovery of ghrelin as the endogenous ligand.

The GH-releasing mechanism follows the standard GHS-R1a pathway: Gq/11-mediated PLC activation, IP3-dependent calcium mobilization, and GH vesicle exocytosis from pituitary somatotrophs. GHRP-6 also suppresses somatostatin and stimulates hypothalamic GHRH release. What distinguishes GHRP-6 from later GHRPs is its pronounced ghrelin-mimetic effect on appetite regulation — it strongly activates orexigenic NPY/AgRP neurons in the hypothalamic arcuate nucleus, producing intense hunger within 20-30 minutes of injection.

This strong appetite stimulation, while problematic for those seeking fat loss, makes GHRP-6 potentially useful in clinical settings involving cachexia, anorexia, or conditions requiring caloric intake increase. GHRP-6 also demonstrates cytoprotective properties in various tissues. Research has shown protective effects in cardiac tissue (reducing ischemia-reperfusion injury), hepatic tissue (attenuating fibrosis in animal models), and gastric mucosa. These cytoprotective effects appear to be mediated through pathways independent of GH release, involving anti-inflammatory and anti-apoptotic signaling. The compound also elevates cortisol and prolactin to a moderate degree, though less than hexarelin.

Ipamorelin is a pentapeptide growth hormone secretagogue that binds selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor that endogenous ghrelin activates. However, unlike ghrelin and other GHRPs such as GHRP-6 and Hexarelin, ipamorelin demonstrates remarkable selectivity — it stimulates robust GH release while causing minimal elevation of cortisol, prolactin, and ACTH at therapeutic doses.

At the molecular level, ipamorelin binding to GHS-R1a on pituitary somatotrophs activates a Gq/11-coupled signaling cascade that stimulates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C. The resulting rise in intracellular calcium triggers GH vesicle exocytosis. This mechanism is distinct from and synergistic with the cAMP pathway activated by GHRH, which is why combining ipamorelin with a GHRH analogue like CJC-1295 produces amplified GH pulses.

The selectivity of ipamorelin is attributed to its specific binding conformation at the GHS-R1a receptor, which activates the GH release pathway without engaging the broader hypothalamic-pituitary-adrenal axis. It does not significantly activate appetite centers in the hypothalamus at standard doses, nor does it stimulate ACTH release from corticotrophs. This clean side-effect profile has made it the most widely prescribed growth hormone secretagogue in anti-aging and regenerative medicine, often considered the safest starting point for patients new to GH-optimizing peptide therapy.